← back to search

Robert M. Prins

APLA Health · US
Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, Glioma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, and CAR-T cell therapy research.
h-index
52
citations
16,533
works
483
NIH funding
primary concept
Medicine
email

Recent publications

A human tumor-immune organoid model of glioblastoma
Cell Reports 2026cited by 7position: middledoi
Predictable clonal hierarchies from restricted progenitors provide a framework for cell type-specific therapies in glioblastoma
2026cited by 2position: contributordoi
Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma
Cancer Research 2026cited by 0position: contributordoi
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence
Cancer Cell 2025cited by 11position: middledoi
Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety
Molecular Therapy 2025cited by 10position: middledoi
Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure
Cell Reports Medicine 2025cited by 7position: middledoi
The activity of cold atmospheric plasma against high-grade glioma: a review
Journal of Neuro-Oncology 2025cited by 4position: middledoi
A Human Tumor-Immune Organoid Model of Glioblastoma
2025cited by 3position: contributordoi
The T-cell receptor repertoire: A window into pediatric brain tumor immunity.
2025cited by 1position: contributordoi
CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES
Neuro-Oncology 2025cited by 0position: middledoi
Supplementary Figure 1 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
Supplementary Figure 5 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
Supplementary Figure 3 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
Supplementary Data 2 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
Figure 5 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
Supplementary Figure 2 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
Supplementary Figure 6 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
Supplementary Data 1 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
Supplementary Figure 4 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2025cited by 0position: contributordoi
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Nature Communications 2024cited by 59position: lastdoi
IL-13Rα2/TGF-<b>β</b> bispecific CAR-T cells counter TGF-<b>β</b>-mediated immune suppression and potentiate anti-tumor responses in glioblastoma
Neuro-Oncology 2024cited by 52position: middledoi
IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
2024cited by 49position: contributordoi
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
2024cited by 44position: contributordoi
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort
Nature Communications 2024cited by 28position: middledoi
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.
2024cited by 20position: contributordoi
Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma.
2024cited by 6position: contributordoi
Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
2024cited by 1position: contributordoi
Figure 2 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2024cited by 0position: contributordoi
Supplementary Figure 1 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2024cited by 0position: contributordoi
Figure 4 from Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 98 papers (2019–2026)Linda M. Liau · Los Angeles Medical Center66 papers (2019–2026)Richard G. Everson · Neurobehavioral Systems66 papers (2019–2025)Lu Sun · First Affiliated Hospital of Henan University58 papers (2024–2025) · 57 papers (2024–2026)Kevin Li · 56 papers (2024–2025)Albert Lai · APLA Health56 papers (2024–2025) · 56 papers (2024–2025)Terry J. Prins · University of California, Los Angeles56 papers (2024–2025)Tie Li · UCLA Medical Center56 papers (2024–2025)Thomas J. Lai · University of California, Los Angeles56 papers (2024–2025)Janet Treger · UCLA Health56 papers (2024–2025)Timothy F. Cloughesy · UCLA Medical Center25 papers (2012–2024) · 24 papers (2019–2023)David H. Munn · University of Sussex22 papers (2020–2023)April Bell · Loyola University Chicago21 papers (2020–2023)Derek A. Wainwright · Loyola University Chicago21 papers (2020–2023)Ursula Grohmann · University of Perugia21 papers (2020–2023)George C. Prendergast · Lankenau Institute for Medical Research21 papers (2020–2023)Erik Ladomersky · AbbVie (United States)21 papers (2020–2023)